Table 3.
Percentages of resistant phenotypes among Gram-positive and Gram—negative isolates by year, 2004–2012
| Pathogen | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2004-12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Gram-positive | |||||||||||
| E. faecalis, VRE | 969 | 0 (0.0) | 0 (0.0) | 1 (1.5) | 0 (0.0) | 0 (0.0) | 2 (1.1) | 1 (0.7) | 1 (3.8) | 2 (1.3) | 7 (0.7) |
| E. faecium, VRE | 332 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (4.9) | 8 (10.8) | 2 (3.3) | 3 (5.5) | 1 (6.7) | 2 (4.3) | 18 (5.4) |
| S. aureus, MRSA | 2229 | 34 (34.3) | 20 (31.7) | 40 (30.5) | 88 (29.6) | 135 (28.2) | 77 (20.0) | 75 (26.1) | 15 (23.4) | 147 (34.7) | 631 (28.3) |
| S. pneumoniae, PRSP | 990 | 0 (0.0) | 1 (3.4) | 3 (4.6) | 3 (2.0) | 9 (4.5) | 7 (4.0) | 6 (4.1) | 0 (0.0) | 3 (2.0) | 32 (3.2) |
| Gram-negative | |||||||||||
| A. baumannii, MDR | 1161 | 0 (0.0) | 0 (0.0) | 2 (2.0) | 7 (4.9) | 12 (5.2) | 12 (5.2) | 13 (6.7) | 1 (3.0) | 7 (4.7) | 54 (4.7) |
| E. coli, ESBL | 2284 | 3 (3.0) | 2 (3.7) | 8 (4.6) | 18 (6.5) | 58 (11.8) | 75 (17.5) | 46 (13.9) | 13 (16.9) | 52 (14.9) | 275 (12.0) |
| H. influenzae, BL-Pos | 1191 | 13 (23.2) | 6 (23.1) | 17 (27.4) | 30 (18.1) | 53 (21.1) | 56 (25.0) | 36 (23.7) | 13 (27.7) | 45 (21.7) | 269 (22.6) |
| K. pneumoniae, ESBL | 1524 | 5 (7.6) | 5 (9.3) | 9 (10.3) | 20 (12.3) | 64 (18.6) | 47 (16.4) | 58 (24.9) | 11 (22.0) | 55 (23.0) | 274 (18.0) |
| P. aeruginosa, MDR | 1780 | 2 (2.5) | 0 (0.0) | 17 (11.2) | 23 (10.7) | 39 (10.2) | 37 (11.0) | 33 (12.5) | 9 (14.8) | 21 (8.1) | 181 (10.2) |
ESBL, extended-spectrum β-lactamase; BL-Pos, β-lactamase-positive; MDR, multidrug-resistant; MRSA, methicillin-resistant S. aureus; PRSP, penicillin-resistant S. pneumoniae; VRE, vancomycin-resistant Enterococcus.
Results do not exactly match those presented by Nørskov-Lauritsen et al. [7] due to subsequent addition and deletion of isolates from the T.E.S.T. database.